TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
44 hedge funds and large institutions have $39M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 6 closing their positions.
115% more call options, than puts
Call options by funds: $439K | Put options by funds: $204K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
0% more funds holding
Funds holding: 44 → 44 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
33% less capital invested
Capital invested by funds: $58.4M → $39M (-$19.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$3.32M |
| 2 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$608K |
| 3 |
Millennium Management
New York
|
+$590K |
| 4 |
Renaissance Technologies
New York
|
+$565K |
| 5 |
TI
Telemetry Investments
New York
|
+$383K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.07M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$366K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$205K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$147K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$113K |
TCON Hedge Fund Activity: Q3 2021 in Review
44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2021, worth a combined $39M — down 33% from $58.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TCON positions and 6 closed out — a net gain of 2 holders — while 11 added to existing stakes and 11 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $3.32M. The largest seller was Deutsche Bank, cutting an estimated $1.07M.
- 44 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $39M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2021, down 33% quarter-over-quarter.
- 8 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +2 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2021 was Altium Capital Management, an estimated $3.32M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2021 was Deutsche Bank, an estimated $1.07M sold.
Based on aggregated 13F filings for Q3 2021.